Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 280

Sort by

Sort Order Select

Journal Articles

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Blood (2021) 138 (7): 571–583.

https://doi.org/10.1182/blood.2021010735

Published: 2021

Includes: Supplemental data

Journal Articles

Prolonged maintenance of hematopoietic stem cells that escape from thrombopoietin deprivation

Ayako Nakamura-Ishizu, Desmond Wai Loon Chin, Takayoshi Matsumura, Darren Qiancheng Tan, Makiko Mochizuki-Kashio, Deng Jianwen, Toshio Suda

Blood (2021) 137 (19): 2609–2620.

https://doi.org/10.1182/blood.2020005517

Published: 2021

Includes: Supplemental data

Journal Articles

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

Régis Peffault de Latour, Sylvie Chevret, Anna Lisa Ruggeri, Felipe Suarez, Laetitia Souchet, David Michonneau, Flore Sicre de Fontbrune, Tereza Coman, Nathalie Dhedin, Marie Thérèse Rubio, Stéphanie Nguyen, Mohamad Mohty, Gérard Socié

Blood (2020) 135 (3): 227–229.

https://doi.org/10.1182/blood.2019000358

Published: 2020

Includes: Supplemental data

Journal Articles

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Yihong Guan, PhD, Bhumika J. Patel, MD, Metis Hasipek, PhD, Dale Grabowski, BS, Hassan Awada, MD, Cassandra M Kerr, MS, Valeria Visconte, PhD, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 453.

https://doi.org/10.1182/blood-2019-131525

Published: 2019

Journal Articles

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

Hanny Al-Samkari, MD, Aric D Parnes, MD, Katayoon Goodarzi, MD, James I Weitzman, MD, Jean M. Connors, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 389.

https://doi.org/10.1182/blood-2019-123864

Published: 2019

Journal Articles

Deviation from Guidelines in Use of Eltrombopag and Romiplostim in Clinical Practice for Children with Primary Immune Thrombocytopenia; Multi-Center Egyptian Experience

Mohsen Saleh Elalfy, MD, Tamer Hassan, MD, Khalid Elsayh, MD, Mohamed Maebid, MD, Hoda Hassab, MD, Rasha Elashry, MD, Mona El ghamrawy, MD, Mahmoud Elhawy, MD, Marwa Zakaria, MD, Mohamed Elshanshory, MD

Blood (2019) 134 (Supplement_1): 4907.

https://doi.org/10.1182/blood-2019-121994

Published: 2019

Journal Articles

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

David Hughes, PharmD, Frances Blevins, PA-C, Bhavesh Shah, RPh, Shayna Sarosiek, Adam Lerner, MD, John Mark Sloan, MD

Blood (2019) 134 (Supplement_1): 4912.

https://doi.org/10.1182/blood-2019-124740

Published: 2019

Journal Articles

Retrospective Evaluation of the Use of Romiplostim after Hematopoietic Stem Cell Transplantation0

Elisabetta Xue, MD, Tatiana Lawrence, MD, Terry B. Gernsheimer, MD, Filippo Milano, MD PhD

Blood (2019) 134 (Supplement_1): 5660.

https://doi.org/10.1182/blood-2019-128673

Published: 2019

Journal Articles

Chitinase 3-like 1 Produced By Fibrocytes Promotes Myelofibrosis

Blood (2019) 134 (Supplement_1): 4197.

https://doi.org/10.1182/blood-2019-125525

Published: 2019

Journal Articles

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

James B. Bussel, MD, Alexandra Kruse, Caroline Kruse, Jody Shy, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 1076.

https://doi.org/10.1182/blood-2019-131351

Published: 2019

Journal Articles

Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry

Blood (2019) 134 (Supplement_1): 1083.

https://doi.org/10.1182/blood-2019-122821

Published: 2019

Journal Articles

Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study

Marc Michel, Marco Ruggeri, Tomás José González-López, MD, Stephane Cheze, MD, Waleed Ghanima, MD PhD, Tor Henrik Anderson Tvedt, Mikael Ebbo, MD PhD, James B. Bussel, MD, Bertrand Godeau, MD

Blood (2019) 134 (Supplement_1): 1081.

https://doi.org/10.1182/blood-2019-122595

Published: 2019

Journal Articles

Comparing the Risk of Complications for Second-Line Treatments of Immune Thrombocytopenia in Veterans: A U.S. National Study

Natalia Ruiz-Negron, PharmD, Jacob Crook, MStat, Matthew T. Rondina, MD, Pallavi Patwardhan, PhD, Qayyim Said, PhD, Isha Desai, MPH, Richard Nelson, PhD, Joanne LaFleur, PharmD, MSPH

Blood (2019) 134 (Supplement_1): 85.

https://doi.org/10.1182/blood-2019-121894

Published: 2019

Journal Articles

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Blood (2019) 134 (Supplement_1): 2998.

https://doi.org/10.1182/blood-2019-129047

Published: 2019

Journal Articles

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Guillaume Moulis, MD PhD, Manuela Rueter, MSc, Margaux Lafaurie, PharmD, Maryse Lapeyre-Mestre, MD PhD, Carmen investigators Group

Blood (2019) 134 (Supplement_1): 2372.

https://doi.org/10.1182/blood-2019-126000

Published: 2019

Journal Articles

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Tomas Jose Gonzalez-Lopez, Fernando Fernandez-Fuertes, Maria Cristina Pascual Izquierdo, PhD MD, Isabel Caparros, Silvia Bernat, Carmen Pastoriza, Maria Paz Martínez-Badas, Pável E Olivera, MD, Gonzalo Caballero, MD, Jose Angel Hernandez-Rivas, MD PhD, Daniel Martínez-Carballeira, MD, Inmaculada Soto Ortega, Gloria Perez Segura, Isabel Regalado, Blanca Sánchez-González, Isidro Jarque, Luis Javier garcia Frade, MD, Miguel A. Sanz

Blood (2019) 134 (Supplement_1): 2352.

https://doi.org/10.1182/blood-2019-129274

Published: 2019

Journal Articles

Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis

Zhi-Jian Liu, PhD, Emoke Deschmann, MD, Haley E. Ramsey, PhDMSc, Henry Feldman, Bethan Psaila, MD PhD, Nichola Cooper, MD MRCP, Evangelia Vlachodimtropoulou Koumoutsea, MBBS,PhDBSc, John B. Porter, MA MDFRCP FRCPath, James B. Bussel, MD, Michael Georgieff, MD, Martha Sola-Visner, MD

Blood (2019) 134 (Supplement_1): 2475.

https://doi.org/10.1182/blood-2019-131895

Published: 2019

Journal Articles

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Blood (2019) 134 (Supplement_1): 2361.

https://doi.org/10.1182/blood-2019-122237

Published: 2019

Journal Articles

Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)

Anwar A. Sayed, MBBS, MSc, PhD, Amna Malik, PhD, Grace Ayoola, BSc., Elisa Lucchini, MD, Sasfia Candrianita, MD, Michelle H Tan, BSc, Camelia Vladescu, MSc, Deena Paul, Alice C J Hart, MBBS, BSc, MRCP, FRCPath(Haem), Ahmad Khoder, MD PhD MRCP, ASCP, Nesrina Imami, PhD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 2364.

https://doi.org/10.1182/blood-2019-122848

Published: 2019

Journal Articles

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Blood (2019) 134 (Supplement_1): 2370.

https://doi.org/10.1182/blood-2019-125580

Published: 2019

NARROW

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Prolonged maintenance of hematopoietic stem cells that escape from thrombopoietin deprivation

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

Deviation from Guidelines in Use of Eltrombopag and Romiplostim in Clinical Practice for Children with Primary Immune Thrombocytopenia; Multi-Center Egyptian Experience

Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center

Retrospective Evaluation of the Use of Romiplostim after Hematopoietic Stem Cell Transplantation0

Chitinase 3-like 1 Produced By Fibrocytes Promotes Myelofibrosis

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry

Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study

Comparing the Risk of Complications for Second-Line Treatments of Immune Thrombocytopenia in Veterans: A U.S. National Study

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers

Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP)

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only